Microalgae Glycosylated Polypeptide Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing therapeutic glycoproteins in eukaryotic host systems, such as yeast, plants, or animal cells, often result in proteins with immunogenic and hypermannosylated forms that are not suitable for human use due to differences in glycosylation patterns, leading to reduced efficacy and safety concerns.
Innovation Solution
Transformed microalgae, like Phaeodactylum tricornutum, are used to produce glycosylated polypeptides with specific glycosylation patterns suitable for therapeutic purposes by expressing enzymes such as N-acetylglucosaminyltransferases and mannosidase II, which generate Man 5 GlcNAc 2 to Man 9 GlcNAc 2 structures without adding immunogenic epitopes like β(1,2)-linked xylose or α(1,3)-linked fucose, thereby mimicking human glycosylation patterns.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If therapeutic proteins are produced in eukaryotic host systems such as yeast, plants, or animal cells, then protein production is achieved, but the glycosylation patterns differ from human patterns resulting in immunogenic and hypermannosylated forms
Solution Approach 1:
The patent applies parameter changes by modifying the host organism from conventional eukaryotic systems (yeast, plants, animal cells) to microalgae, which naturally possess a glycosylation system that produces human-like glycan structures. This fundamental parameter change in the biological system resolves the contradiction by enabling therapeutic protein production with appropriate human-compatible glycosylation patterns, thereby reducing immunogenicity while maintaining productivity
Solution Approach 2:
The patent employs copying by utilizing the endogenous microalgal glycosylation system that naturally produces glycan structures similar to human glycosylation patterns. Instead of attempting to modify conventional eukaryotic systems to copy human glycosylation, the invention selects microalgae whose native glycosylation system already closely resembles human patterns, thus copying the desired human-like glycosylation characteristics without the need for extensive genetic engineering
2Productivity
If conventional eukaryotic host systems are used for protein production, then protein expression is achieved, but the systems require costly and complex infrastructure with higher contamination and pathogen transmission risks
Solution Approach 1:
The patent applies this principle by selecting microalgae as a disposable, single-use production system that can be rapidly cultured and discarded after protein harvest. Microalgae systems do not require the complex, expensive, and highly regulated infrastructure needed for mammalian cell culture, eliminating the need for costly bioreactors, specialized media, and extensive contamination control measures while maintaining high protein expression levels
Solution Approach 2:
The patent segments the production system by using microalgae that can be grown in simple, scalable cultures separate from complex animal or plant tissue systems. This segmentation allows for streamlined processing where microalgae can be directly harvested and processed without the need for complex tissue culture infrastructure, reducing overall system complexity while maintaining productivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the production of glycoproteins with human-like glycosylation patterns in high yield, reducing immunogenicity and improving therapeutic efficacy and safety by avoiding the need for costly and complex animal or plant-based systems, while also minimizing the risk of contamination and pathogen transmission.
Implementation Method 1
expressing enzymes such as N-acetylglucosaminyltransferases and mannosidase II, which generate Man 5 GlcNAc 2 to Man 9 GlcNAc 2 structures
Data Source
Figure 1
Figure 1
Figure 2(a)~2(b)
AI summary
The invention relates to transformed microalgae capable of expressing glycosylated polypeptides and methods for producing said transformed microalgae and producing glycosylated polypeptides.